Bacillus Calmette‐Guérin perfusion therapy for carcinoma in situ of the upper urinary tract

Abstract

Objective To analyse the clinical and therapeutic conse-after the treatment was completed. The remaining two patients (three pyelo-ureteric systems) had persistently quences of bacillus Calmette-Guérin (BCG) perfusion therapy for carcinoma in situ (CIS) of the upper positive cytology. Of two patients who received BCG therapy through a ureteric catheter, one developed a urinary tract. Patients and methods Eight pyelo-ureteric systems in ureteric stricture and the other developed renal tuberculosis. five patients with cytologically confirmed CIS of the upper urinary tract were treated using perfusion of Conclusions Although long-term adaptation to a nephrostomy tube disturbs the quality of life of the BCG through a percutaneous nephrostomy tube in five and a retrograde ureteric catheter in three. Follow-patient, percutaneous perfusion therapy through a nephrostomy tube seems to be safer than retrograde up cystoscopy, retrograde pyelography and selective urinary cytology were obtained 4 weeks after the last perfusion through a ureteric catheter. Keywords Carcinoma in situ, bacillus Calmette-Guérin treatment and every 3 months thereafter. Results In three patients (five pyelo-ureteric systems) vaccine, upper urinary tract, percutaneous perfusion the cytology remained negative for 10-46 months and total cystectomy for CIS of the upper tract and

Clinical outcome of bacillus Calmette‐Guérin perfusion therapy for carcinoma in situ of the upper urinary tract

“…Recently, we have tended to select a retrograde ureteric catheterization using the Double-J stent, because this method makes it possible to administer BCG without hospitalization. In addition, consistent with previous studies, 4,[8][9][10][11][12][13][14] the present results suggest that the efficacy of this method may be similar to others, if VUR was S-J + D-J 100 9-38 Okubo et al 12 …”

“…One of the primary concerns for intrarenal BCG therapy is choosing when to convert to surgical treatment in cases of recurrence. In eight previously reported studies of intrarenal BCG therapy for CIS of the upper urinary tract, 4,[8][9][10][11][12][13][14] 75 renal units were treated according to the same criteria used in the present study, and 20 of the 75 units (27%) showed no response either recurrence. In 20 of these patients, 7 underwent surgical treatment, whereas radiologically documented invasive tumors developed in 9 of the remaining 13 patients.…”

“…Previous studies have reported several advantages and disadvantages in each method. [9][10][11] For example, percutaneous BCG instillation is the most reliable method of perfusion of BCG in the renal pelvis; 4 however, it is relatively invasive, and can possibly cause the implantation of cancer cells along the nephrostomy tract. Recently, we have tended to select a retrograde ureteric catheterization using the Double-J stent, because this method makes it possible to administer BCG without hospitalization.…”

“…2 However, only a few studies have analyzed the efficacy of BCG therapy for CIS of the upper urinary tract. [3][4][5][6][7][8][9][10][11][12] Therefore, several points need to be elucidated, especially the most appropriate therapeutic strategy in patients with a poor response or recurrence of CIS after intrarenal BCG therapy. Therefore, in the present study, we retrospectively reviewed our experience of BCG instillation for patients with CIS of the upper urinary tract, and evaluated its efficacy and safety.…”

Intracavitary Therapy of Noninvasive Transitional Cell Carcinomas of the Upper Urinary Tract

“…Due to the appealing results, BCG intracavitary therapy gained interest and was then used as prophylaxis by some authors in pilot trials [19,20,[33][34][35][36] after anterograde or retrograde endourological treatment of papillary tumors or as therapy for residual disease [2, 32,34,35,[37][38][39][40], particularly carcinoma in situ [37][38][39][40][41].…”